Jianfeng Group Lin2016 -021 (Announcement of Letter of Intent for Limin Chemical Cooperation)
Release time:
2020-08-05
Securities Code: 600668 Securities Abbreviation: Jianfeng Group Announcement No.: 2016-021
Bond Abbreviation: 13 Peak 01 Bond Code: 122227
Bond Abbreviation: 13 Peak 02 Bond Code: 122344
Zhejiang Jianfeng Group Co., Ltd.
Prompt Announcement on Subsidiaries Signing Letter of Intent for Cooperation
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and shall bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Important Content Reminder:
l Transaction Brief Content: Zhejiang Jianfeng Pharmaceutical Co., Ltd., the company's holding subsidiary, recently signed a Letter of Intent for Cooperation with Zhejiang Limin Holding Co., Ltd. to cooperate with it in the pharmaceutical intermediate business.
l This transaction does not constitute a related party transaction
l This transaction does not constitute a major asset reorganization
l This is a letter of intent for cooperation, which is the basis of cooperation negotiations. There is uncertainty as to whether the cooperation can be realized.
Overview of 1. Foreign Investment
(I) Zhejiang Jianfeng Pharmaceutical Co., Ltd. (hereinafter referred to as "Jianfeng Pharmaceutical"), a subsidiary of the Company, recently signed a "Letter of Intent for Cooperation" with Zhejiang Limin Holdings Co., Ltd. (hereinafter referred to as "Limin Holdings") to carry out cooperation in the pharmaceutical intermediate business based on the pharmaceutical intermediate business segment of the subsidiary of Limin Holdings. The two sides intend to set up a new company in Suichang County, Lishui City, Zhejiang Province, Limin Holdings intends to invest in the physical assets of the pharmaceutical intermediates sector of the following subsidiaries, and Peak Pharmaceuticals intends to contribute in cash.
(II) signed a letter of intent for cooperation, which is the basis for cooperation negotiations. Specific matters need to be further negotiated according to the results of audit, evaluation and due diligence. The formal cooperation agreement will also be reviewed through the decision-making process in accordance with the "Stock Listing Rules" and the company's "Articles of Association.
(III) The cooperation is not a connected transaction, nor does it constitute a major asset reorganization as stipulated in the Measures for the Administration of Major Asset Reorganization of Listed Companies.
Basic Information of 2. Partners
1 , Enterprise Name: Zhejiang Limin Holding Co., Ltd.
2 , Enterprise Nature: Limited Liability Company
3 , Place of Registration:
4 , Changlian Village, Yunfeng Street, Suichang County, Zhejiang Province, Date of Registration: 2016# April 11, 75
5 , main office location: Changlian Village, Yunfeng Street, Suichang County, Zhejiang Province
6 , legal representative: Li Feng
7 , registered capital: Limin Holding's registered capital is 5250 yuan, and the paid-in capital as of the announcement date is 15 million yuan.
8 , main business: industrial investment
9 , major shareholders:
Serial Number |
Shareholder Name or Name |
Contribution (RMB 10,000) |
Contribution Proportion |
1 |
li Feng |
1761.375 |
33.550 |
2 |
Lishui Lihe Investment Partnership |
177.1875 |
3.375 |
3 |
Lishui Lishun Investment Partnership |
177.1875 |
3.375% |
4 |
Lishui Lichang Investment Partnership |
177.1875 |
3.375% |
5 |
Lishui Lian Investment Partnership |
177.1875 |
3.375 |
6 |
Lishui Lizi Investment Partnership |
259.875 |
4.95% |
Another, mr. Li Feng is the managing partner of the above 2-6 partnership, accounting for 2.22 of Lishui Lihe Investment Partnership, 2.22 of Lishui Lishun Investment Partnership, 6.67 of Lishui Lichang Investment Partnership, 2.22 of Lishui Lian Investment Partnership and 40.91 of Lishui Liqi Investment Partnership.
Basic Information on 3. Cooperation Target
(I) This cooperation is to be relocated and transformed based on the pharmaceutical intermediate business segment of Zhejiang Limin Chemical Co., Ltd. (hereinafter referred to as "Limin Chemical") controlled by Limin Holdings to carry out cooperation in pharmaceutical intermediate business.
(II) Limin Chemical was established on May 29, 1998 . The current registered capital is 35 million yuan, of which: Limin Holdings accounts for 42.86 as the largest shareholder and Li Feng accounts for 15.6; The residence is Zhuangshan, Suichang County, Zhejiang Province. Mainly engaged in civil blasting equipment, chemical products and other related products. The main products of the chemical sector are: SP-80 emulsifier, 2-imidazolidinone, 1-chloroformyl-2-imidazolidinone products.
(III) As of the end of 2015 , Limin Chemical had total assets of 169.3742 million yuan, net assets of 57.3046 million yuan, operating income of 140.036 million yuan in 2015 (including operating income of chemical intermediates of about 45 million yuan) and net profit of 9.1185 million yuan. As of the end of the first quarter of 2016, Limin Chemical had total assets of 168.2613 million yuan and net assets of 58.2794 million yuan, in the first quarter of 2016, the operating income was 32.6912 million yuan (including the operating income of chemical intermediates was about 13.88 million yuan) and the net profit was 933800 yuan. The above financial data has not been audited by an accounting firm with securities qualification.
Main Contents of Letter of Intent for 4. Cooperation
On May 10, 283, 2016 , Limin Holdings (Party A) and Jianfeng Pharmaceutical (Party B) signed the Letter of Intent for Cooperation, with the main terms as follows:
(I) Cooperation ModeParty A and Party B intend to cooperate on the basis of Party A's existing pharmaceutical intermediate business sector and set up a new company in Suichang County. Party A intends to contribute the physical assets of the pharmaceutical intermediate sector and Party B intends to contribute in cash. The scope of business is mainly bulk drugs, pharmaceutical intermediates, etc. The registered capital and contribution ratio of the specific company shall be negotiated separately.
(II) Follow-up Work Arrangement
1
. Both parties jointly set up a working group to carry out preliminary certification of the project and carry out other related work.
2. Party A shall confirm the rights and assets of the physical assets to be invested, and make preliminary preparations such as audit, evaluation and due diligence. Coordinate with the local government and relevant departments to do a good job in the site selection arrangement of the cooperation project, land supply, environmental assessment approval, industrial and commercial registration, and strive for preferential tax policies and other affairs related to the cooperation project.
3, do a good job in product selection, investment budget and other preliminary feasibility study work.
(III) exclusive matters1
, unless approved in writing by party B, within 6 months after the signing of this agreement (hereinafter referred to as exclusive period), party A and any representative under its control shall not, directly or indirectly, seek to engage, negotiate, negotiate or sign any agreement or letter of intent with any third party (whether or not such agreement or letter of intent is binding on it) with respect to any matter agreed upon in this Agreement.
5. the impact of this cooperation on the company and risk tipsThis cooperation is based on the company's strategic plan to expand and strengthen the pharmaceutical business. If the cooperation can be successfully completed, on the one hand, it will establish a production base for pharmaceutical intermediate raw materials of Jianfeng Pharmaceutical, laying a foundation for the further development of the company's pharmaceutical business; on the other hand, it can also realize the extension and development of the peak pharmaceutical industry chain.
In view of the letter of intent signed this time, further negotiations are needed on the basis of audit, evaluation and due diligence. The specific cooperation mode and investment scale will also perform the deliberation procedures of the board of directors or the general meeting of shareholders in accordance with the provisions of the stock listing rules and the articles of association of the company; the site selection and environmental assessment of the project relocation and transformation also need the approval of relevant government departments. There is uncertainty about whether the cooperation can be realized. The company will disclose the follow-up progress in a timely manner according to the progress of the cooperation. Investors are kindly requested to pay attention to investment risks.
hereby announce
Zhejiang Jianfeng Group Co., Ltd.
Board of Directors
May 10, 2016
More information
Pharmaceutical Company Established New Drug R & D Promotion Committee
Recently, the new drug research and development promotion committee of Jianfeng pharmaceutical company was formally established, which will be responsible for promoting the new drug research and development progress of pharmaceutical companies and subordinate enterprises, and coordinating the new drug research and development work of various departments and subordinate enterprises. The New Drug Promotion Committee is headed by Huang Jinlong, deputy general manager of the group and general manager of the pharmaceutical company, and Jiang Hong, deputy general manager of the pharmaceutical company, is headed by Pang Xiong, Shi Cunyuan, Xu Lizhen, Yu Jingjing, Zheng Kunwu, Feng Lixiang, Kang Litao, Li Qian, Wu Chonggui, Zhai Tsunami, Huang Fang and Tong Xiaojun. The committee has an office, and Shi Cunyuan is also the director of the office, responsible for the supervision, communication, and coordination of the company's new drug research and development projects. The main responsibilities of the new drug promotion committee include: organizing the establishment and improvement of the R & D project management system and relevant regulations of the pharmaceutical company; organizing the formulation of the development plan of the new drug R & D project of the pharmaceutical company and supervising the implementation; making decisions on project initiation and participating in project evaluation; supervising the management of new drug R & D of the pharmaceutical company and providing guidance; Responsible for the process management of new drug R & D projects and the promotion and coordination of new drug R & D; carry out the assessment of new drug research and development projects; issue the responsibility system assessment and task statement of new drug research and development projects; be responsible for solving major technical problems in the process of new drug research and development; be responsible for the research and improvement of the management mode of research and development projects of pharmaceutical companies; be responsible for the future trend analysis of new drug research and development projects; review the major scientific research achievements of pharmaceutical companies and put forward reward suggestions. Huang Jinlong said that the research and development of new drugs is an important foundation for the healthy development of the pharmaceutical industry and is a systematic project. Jianfeng Pharmaceutical has always attached great importance to the research and development of new drugs, but there is still a certain gap between the progress of research and development and the development process of the enterprise, and the lack of coordination in the research and development process also affects the progress and quality of new drug research and development to a certain extent. The purpose of the establishment of the New Drug Research and Development Promotion Committee is to solve the progress of new drug research and development, to find and solve problems in time, to implement more targeted, and to effectively integrate enterprise resources, improve the speed and quality of new drug research and development, and make good product reserves for the healthy development of pharmaceutical companies. (Reporter Ni Yingzhen)
2020
09-11
Jianfeng Pharmaceutical ranks among the top 100 Chinese pharmaceutical industries in 2019
On August 25, the "2019 Top 100 Series List of China's Pharmaceutical Industry" was released in Kunming. Zhejiang Jianfeng Pharmaceutical Company was shortlisted as one of the top 100 enterprises in China's pharmaceutical industry. The product Berunning (Olopatadine Hydrochloride Eye Drops) was selected as the "Most Growing Product Brand" of China's pharmaceutical industry ". The "Top 100 Pharmaceutical Industry Series List" was evaluated and released by Guangzhou Punctuation Pharmaceutical Information Co., Ltd., a subsidiary of the Southern Institute of Pharmaceutical Economics of the State Drug Administration, and is known as the "Oscar in Chinese Pharmaceutical Industry. Southern Institute is the earliest institution in China that specializes in pharmaceutical industry policy and market economy research, pharmaceutical market research, pharmaceutical economic data analysis and research, and pharmaceutical professional media publishing. It is in the field of market information value-added services and media communication and marketing services in China's pharmaceutical and health industry., The field of professional quality improvement has extremely extensive influence. The "Top 100 Pharmaceutical Industry" is comprehensively evaluated by the company's annual pharmaceutical industry sales revenue, total profit and R & D investment results. On the same day, the "most growing product brand" of Chinese medicine selected by the Southern Institute's media "Pharmaceutical Economic News" was released simultaneously. Spike Pharmaceuticals product Beirunning (Olopatadine Hydrochloride Eye Drops) was selected. (Xu Yuting)
2020
09-01
Company Disclosure 2020 Semi-Annual Report
On August 28, the Group held the 16th meeting of the 10th Board of Directors of the Company by means of communication, and considered and adopted the "2020 Semi-Annual Report of Jianfeng Group" and the "Proposal on Changes in the Company's Accounting Policy". On August 29, the Company's 2020 semi-annual report was publicly disclosed on the Shanghai Stock Exchange and the Shanghai Securities News and China Securities News. In the first half of the year, the Group focused on the general policy of "grasping projects, making up for shortcomings, improving quality and efficiency, and constantly improving the core competitive advantage", and on the basis of doing a good job in epidemic prevention and control, the Group seized the resumption of work and production, accelerated project construction, and enhanced the core competitiveness of enterprises. In the first half of 2020, the company achieved total operating income of 1.44 billion yuan, net profit attributable to shareholders of 0.368 billion yuan, net profit per share of 1.07 yuan. As of the end of June 2020, the Company's total assets were $5.892 billion, net assets were $4.068 billion, and net assets per share were $11.82. From February to April, affected by the epidemic, the national project construction progress slowed down, cement market demand decreased; after May, the epidemic was effectively controlled, infrastructure investment continued to recover, the real estate industry continued to pick up, cement sales steadily rebounded. During the outbreak, Daye Peak completed the technical transformation projects such as the cold machine, cement mill, into the desulfurization tower anti-corrosion transformation, to ensure the efficient operation of the production equipment after the resumption of work. Yunnan peak rotary kiln production, cement production and other major technical and economic indicators of steady rise; comply with market trends, timely adjustment of marketing policies. Guizhou Jianfeng has promoted the project infrastructure construction, equipment installation and commissioning, raw material bidding and other work in an orderly manner, and through preliminary publicity to enhance the popularity of the Jianfeng brand in the local area, and make a series of preparations for the transformation from project construction to production and operation. In the first half of 2020, the reform of China's medical and health system continued to deepen, and new policies were introduced intensively. Peak Pharmaceuticals and its subsidiaries in the epidemic prevention work at the same time in the first time to achieve the resumption of production, and actively organize donations to support the fight against the epidemic, was named the annual "war epidemic star" the most socially responsible pharmaceutical enterprises. In the first half of the year, Jianfeng Pharmaceutical continued to increase the introduction and development of varieties, and JFAN-1001 applied for clinical application of new anti-tumor drugs. At present, it has obtained the notice of approval for clinical trials. Optimize the production process of API workshop and further shorten the production cycle of raw materials. Continue to improve product sales policies and strengthen market channel control. Shanghai North Carolina further straightened out the internal management structure, production and marketing convergence more smoothly, continue to promote the construction of Anhui North Carolina and Anhui Zhongwang Phase II technical transformation project, promote the peak pharmaceutical raw materials, preparations integration of industrial upgrading strategy. Other business segments of the company actively responded to the challenge of the new crown epidemic and carried out production and operation activities in a standardized and orderly manner. Tianjin natural products company vigorously explore the international and domestic markets, sales revenue to achieve steady growth. Peak Health focuses on the basic idea of "sales orientation, burden reduction and efficiency improvement, fine-grained savings, cost reduction and efficiency enhancement" to effectively improve the operational efficiency of enterprises. Jianfeng International Trade has actively developed new storage business varieties and achieved practical results, and has become the first enterprise in Jinhua to formally obtain the qualification of "network freight. Peak cable seizes the special needs of communication cables such as subways, vigorously promotes large logarithmic cables for subways, and strives to achieve the long tail effect. On the same day, the company also held the 10th meeting of the Ninth Board of Supervisors and reviewed and approved relevant reports. (residual fruit)
2020
09-01
The company organizes new employee induction training
From August 12 to 14, in order to strengthen the training of talents in the group and improve the comprehensive quality of new employees, Jiang Xiaomeng, secretary of the party committee and chairman of the group company, Yu Jianhong, general manager, and other leaders and heads of relevant enterprises and departments conducted a three-day induction training for new employees. New employees from foreign enterprises such as Guizhou Huangping Peak, Daye Peak and Shanghai North Carolina participated simultaneously through online methods. In the course of corporate culture, General Manager Yu Jianhong started from the history of the development and struggle of the peak, divided into five stages: hard work, determined reform, diversified development, strategic adjustment, and strategic development, and introduced in detail the development process of the group company and the current industrial layout., The results achieved; from the aspects of enterprise spirit, vision, development philosophy, values, business philosophy, etc, this paper introduces the peak corporate culture rooted in 62 years of history and inherited in the blood; from the perspective of an enterprise manager and old employees, he speaks a lot of truth to the new employees and puts forward a lot of hopes and suggestions. Chairman Jiang Xiaomeng took "How New Employees Achieve Win-Win with Enterprises" as the topic, and proposed that the key to the success of an enterprise lies in how to select, retain, educate and employ people. Peak and employees complement each other. Peak can achieve today's achievements and the struggle of generations of peak people are inseparable. He also taught new employees the basic concepts that need to be understood, the basic qualities that need to be possessed and the sense of hardship in entering the new environment through 16 key words, and combined with his own experience and quoting from others, he analyzed the core elements of success, the signs of a successful career, the personal qualities that need to be possessed for success, and the importance of establishing a personal knowledge management system, it expresses the ardent hope of new employees to adjust their mentality, keep learning, clear goals, clear dreams, cultivate win-win thinking, and grow up together with the peak. The heads of the human resources department of the group company, the safety management office of the group company, and the comprehensive department of the pharmaceutical company also taught the new employees the corporate rules and regulations and the "Employee Handbook", safety knowledge and professional ethics. The new employees also visited the group exhibition hall and had a deeper understanding of the development history and enterprise achievements of the peak. After the training, the human resources department also organized an examination to test the training effect. (Reporter Chen Shengmu)
2020
08-21
According to this newspaper, through the interconnection monitoring of the transportation department in Zhejiang province, the network freight platform of peak international trading company passed the online service capability audit, interface access audit, eight capability identification and other audit procedures, and successfully obtained the road transportation business license with the qualification of "network freight" on July 2. It is understood that Jianfeng International Trade is currently the first enterprise in Jinhua and Quzhou to obtain this qualification.
2020
08-05
News from our newspaper On July 21, Xi Jinping, General Secretary of the Central Committee of the Communist Party of China, President of the State, and Chairman of the Central Military Commission hosted a symposium for entrepreneurs in Beijing and delivered an important speech. Over the past few days, the General Secretary's speech has aroused strong repercussions in all walks of life. On July 23, Jiang Xiaomeng, chairman of the group company, said in an interview with Jinhua TV that the general secretary's speech was calm and inspiring, and pointed out the direction of future work for entrepreneurs.
2020
08-05